Neoplasms of natural killer (NK)-lineage are rare. Their prognosis is generally poor except for cases of solitary nasal NK-cell lymphoma. The NK-cell Tumor Study Group performed a survey in Japan on patients diagnosed between 1994 and 1998. Of 228 patients selected for analysis, 40 underwent HSCT (15 allografts and 25 autografts). The underlying diseases were myeloid/NK cell precursor acute leukemia (n ¼ 4), blastic NK-cell lymphoma (n ¼ 11), aggressive NK-cell leukemia (n ¼ 3), and nasal-type extranodal NK-cell lymphoma (n ¼ 22). At the time of HSCT, 22 patients were in complete remission (CR), 11 were in relapse, and seven were primary refractory. All patients received myeloablative conditioning regimens including total-body irradiation. Sixteen died of disease progression, and six of treatment-related causes. Overall, 4-year survival was 39% with a median follow-up of 50 months; this was significantly better than that of patients who did not undergo HSCT (21%, P ¼ 0.0003). For patients transplanted in CR, the 4-year overall survival was 68%, which was significantly better than that of patients who went into CR but did not undergo HSCT (P ¼ 0.03). These findings suggest that the HSCT is a promising treatment strategy for NK-cell lineage.
Introduction
Natural killer (NK) cells are lymphocytes with the morphology of large granular lymphocytes, CD3
þ immunophenotype, a major histocompatibility complex unrestricted cytotoxicity, and the germline configuration of T-cell receptor genes; they are now regarded as the third lineage of lymphocytes. [1] [2] [3] Neoplasms arising from NK-cell lineage are rare, even in the East Asia, 4 where the frequency is relatively higher than that in other parts of the world, ranging from 2% in Japan 5 to 8% in Korea. 6 More than half of them present with a solitary lesion of the nasal or nasopharyngeal area, [7] [8] [9] [10] and can be treated with local radiotherapy. [11] [12] [13] However, NK-cell neoplasms generally show poor response to chemotherapy, 7, 9, 14, 15 which is accounted for by the expression of multidrug resistanceassociated p-glycoprotein. 16, 17 The prognosis of patients with advanced stage NK-cell neoplasms is therefore poor, with their reported median survival ranging from 2 to 6 months. 14, 15, 18 Currently, no standard treatment exists for the advanced-stage patients. On the other hand, there have been several anecdotal case reports of success with hematopoietic stem cell transplantation (HSCT) for NKcell neoplasms. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] To investigate the benefit of HSCT for NK-cell lineage neoplasms, we analyzed a large number of cases, and compared the clinical results of patients who were treated with or without HSCT.
Materials and methods

Patients
Between 1994 and 1998, 228 patients with NK-cell lineage neoplasms were identified in a survey by the NK-cell Tumor Study Group. The study was approved by the working committee of the NK-cell Tumor Study Group and the institutional review board of the participating institutions. The diagnostic procedure was described previously. 18, 31 Briefly, specimens were reviewed by two expert hematopathologists (SN and JS), and clinical data were reviewed by the Diagnostic Committee (RS, KK and KO). Patients' follow-up data were reviewed in January 2002. Data from 40 patients who received HSCT were analyzed and compared with those from the others.
Disease definition
On the basis of the discussion at our third NK-Cell Tumor Research Meeting in 1999, diagnostic criteria were defined as previously described. 4, 31 Briefly, myeloid/NK-cell precursor acute leukemia is defined as leukemia without myeloperoxidase and Sudan black B reactivity with a phenotype of CD7 þ , CD56 þ , and myeloid antigens (CD13 or CD33)
þ . [32] [33] [34] Their T-cell receptor (TCR) b and g and immunoglobulin heavy chain (IgH) genes show germ-line configurations, but the TCR d gene may be rearranged. Blastic NK-cell lymphoma is defined as a proliferation of lymphoblastoid cells with CD56
þ /À and myeloid antigen (CD13 and CD33)
À immunophenotype, and germline configuration of TCR b and g, and IgH genes. 33, 35 Aggressive NK-cell leukemia/lymphoma is characterized by the presence of NK cells mainly in the peripheral blood, bone marrow, liver, and spleen, and by a rapidly progressive clinical course with poor outcome. 18 Diagnostic criteria include the presence of more than 30% of large granular lymphocyte with an immunophenotype of surface CD3 
Transplantation
Myeloablative conditioning regimens were used for all patients, and contained total body irradiation for allogeneic transplants. GvHD prophylaxis consisted of shortcourse methotrexate with either cyclosporine or tacrolimus.
Statistics
Correlation between the two groups was examined with the w 2 -test, the Fisher's exact test and the Mann-Whitney U test. Patient survival data were analyzed with the method of Kaplan and Meier, and were compared by using the log-rank test. Univariate and multivariate analyses were performed with the aid of the Cox proportional hazard regression model, and variables were selected with the stepwise method. Data were analyzed with STATA statistical software (College Station, TX, USA).
Results
Characteristics of the 40 patients who underwent HSCT and the 187 who did not are shown in Table 1 . Twenty-five patients received autologous transplantation and 15 received allogeneic transplant. Three cases who received allogeneic transplant have been reported elsewhere. 37 Except for one who received HSCT from an unrelated donor, all allografted patients received transplant from HLA-identical sibling. The duration from diagnosis to transplant varied from 1.2 months to 45 months with a median of 7 months. Details of the patients are listed in Table 2 (autologous transplant) and Table 3 (allogeneic). Eleven patients received transplant in primary refractory state, 22 in complete remission (CR) (16 in the 1st and six in the 2nd remission), and seven during relapse without subsequent remission. All patients transplanted in relapse were refractory to salvage therapy. For non-CR patients, allogeneic transplants were performed more often than were autologous transplants (60 vs 36%), but the difference was not statistically significant (P ¼ 0.29).
All patients but one, who died of multiorgan failure on day 19, could achieve engraftment. Results of the HSCT are listed in Table 2 (autologous) and Table 3 (allogeneic). Eighteen patients are alive and 22 have died, 16 of whom died of progression or recurrence of the primary disease. 
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Six died of transplant-related mortality, five of whom underwent allogeneic transplantation.
The overall survival curves of patients who received transplants and of those who did not are shown in Figure 1a . The long-term survival rate of those who received transplants was 40% at the median follow-up of 51 months after diagnosis, whereas that for those who did not was 25% (median follow-up 32 months), with a statistically significant difference (P ¼ 0.0003). For patients transplanted in complete remission the 4-year overall survival was 68%, which was significantly better than that of those who reached complete remission but did not receive transplant (Figure 1b , P ¼ 0.03).
The long-term survival was 47% for patients who received autologous transplants, and 29% for allografted patients, but the difference was not significant (P ¼ 0.12, Figure 2a ). Unlike the outcome for conventional treatments, no patient died later than 2 years post transplant. Patients who received HSCT when in CR showed significantly better prognosis than those who received HSCT during non-CR (58 vs 24%, P ¼ 0.001; Figure 2b ). The probability of relapse was lower for allografted than for autografted patients (17 and 29%, respectively; Figure 3a ), but the difference was not statistically significant. On the other hand, the probability of transplant-related mortality was significantly higher for allografted than for autografted patients (48 and 4%, respectively, P ¼ 0.001; Figure 3b ).
When the patients were categorized by disease, superior overall survival was noted both for extranodal NK-cell lymphoma (Figure 4a , P ¼ 0.02), and for those with other types of NK-lineage tumors (Figure 4b , P ¼ 0.007). The difference was also significant for patients who achieved complete remission (P ¼ 0.03).
Discussion
Prognosis for advanced NK-lineage neoplasm is invariably poor despite the use of multiagent chemotherapy. The median survival of myeloid/NK cell precursor acute leukemia is 17 months [32] [33] [34] and that of blastic NK cell lymphoma is 12-20 months. 33, 35, 38 Aggressive NK-cell leukemia is highly aggressive with a median survival of only 2 months. 18 Although patients with stage I nasal-type extranodal NK-cell lymphoma show relatively good prognosis, those with more advanced stages show poor prognosis (median survival 4-14 months).
14,15,31 HSCT has been tried as a therapeutic strategy for this rapidly progressive and incurable disease, but the numbers of patients have been limited because of the rarity of the disease. Our study reported here is the first to demonstrate that the prognosis for patients who were treated with HSCT was better than that for patients who were not. For relapsed/refractory cases, four of our patients are alive and well with long and durable remission, which cannot be achieved without HSCT.
For our series of patients with allogeneic transplantation, the probability of relapse was as low as 17%, even though 60% of them received transplant during remission failure. The low incidence of relapse may indicate that there is a graft-versus-lymphoma effect 39, 40 for NK-cell lineage tumors. On the other hand, transplant-related mortality was significantly higher for those who underwent allogeneic transplantation. For patients who can achieve CR, autologous transplantation 19, [21] [22] [23] [24] 26 may be a good choice of treatment, particularly for those who could not find a suitable donor. Allogeneic transplants 23, 25, 27, 29, 30 can be used for patients who have no chance of achieving remission.
In our series, however, the criteria for transplantation were not uniform. It cannot be fully denied that patients (a) The probability of relapse was lower for patients who received allogeneic HSCT, as well as for those who received autologous transplants (P ¼ 0.45). (b) The probability of TRM was significantly higher for those who underwent allogeneic than for those who underwent autologous HSCT (P ¼ 0.001). who received transplant are likely to have had a better performance status, and an overall better chance of survival, which is also not infrequently pointed out for other hematolymphoid malignancies.
In conclusion, HSCT appears to be a promising treatment strategy for NK-cell lineage neoplasms, so prospective studies to confirm its efficacy are warranted.
